(Beijing, Shanghai & Boston), December 1, 2025— Jacobio Pharma (1167.HK) announced that the clinical results of KRAS G12C inhibitor glecirasib in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) have been published in The Lancet Respiratory Medicine , a leading medical journal with an impact factor of 32.8.   This represents the first publication of comprehensive clinical data for all oral combination of a KRAS G12C inhibitor and SHP2 inhibitor, now publicly available in this prestigious journal. 

The open-label Phase 1/2a study enrolled 171 patients with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 previously untreated patients. The results showed that the combination achieved a 71% objective response rate (ORR) and 12.2 months median progression-free survival (mPFS) in the first-line population, outperforming many other first-line KRAS G12C treatment regimens.  These results underscore the potential of this all-oral, chemotherapy-free combination to offer a meaningful clinical alternative for a broad range of patients. The fully oral dosing regimen further enhances treatment convenience and may contribute to improved patient quality of life.

Professor Jie Wang of the Cancer Hospital, Chinese Academy of Medical Sciences, commented:
“While KRAS G12C monotherapy has been approved, challenges remain regarding how to further improve response rates, delay disease progression, and enhance survival and quality of life. The combination of SHP2 and KRAS G12C inhibitors represents a novel therapeutic strategy. The Phase II data clearly demonstrate the therapeutic potential of this combination.”

Andrea Wang-Gillam, M.D., Ph.D., Co-CEO, CMO and Global Head of R&D of Jacobio Pharma, stated: “Since glecirasib received approval in China this May for second-line NSCLC, we have continued to advance its development in  the first-line  setting. The all-oral combination of KRAS G12C and SHP2 inhibitors has the potential to  bring new therapeutic options for patients in China.”

The phase III clinical trial of KRAS G12C inhibitor in combination with SHP2 inhibitor has begun in China, directly comparing the regimen with standard first-line therapy in KRAS G12C–mutated NSCLC, with the goal of bringing world’s first approved SHP2-inhibitor combination to patients.

About Jacobio Pharma
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries. 
For more information, please visit: http://www.jacobiopharma.com